[A22-133] Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V
Last updated 15.06.2023
Project no.:
A22-133
Commission:
Commission awarded on 21.12.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Indication:
Adults with moderately to severely active Crohn’s disease
Result of dossier assessment:
- who have had an inadequate response to, lost response to, or were intolerant to conventional therapy: added benefit not proven
- who have had an inadequate response to, lost response to, or were intolerant to a biologic therapy (TNF-alpha antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-156 | Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-41 | Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-40 | Risankizumab (Crohn disease) – Addendum to Commission A22-133 | Commission completed |
Federal Joint Committee (G-BA)
2023-06-15 A G-BA decision was published.